\
Lyrica® 利痛抑®

Lyrica® 利痛抑®是一種神經傳遞物抑制劑,能把腦內過度活躍的神經細胞回復至正常水平1-2。利痛抑®已獲美國食物及藥物監督管理局及歐盟認可3-4。
參考資料:
- Kavoussi, Richard. "Pregabalin: From Molecule to Medicine." European Neuropsychopharmacology 16.2 (2006): S128-133. Web.
- Lyrica® (pregabalin) Prescribing Information. Pfizer Corporation Hong Kong Limited. Version January 2018.
- US. Food and Drug Administration. Approved drug products: Lyrica Pregabalin. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021446. Accessed on 19 June 2019.
- European Medicine Agency. Lyrica Pregabalin authorization details. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica. Accessed on 18 June 2019.
[PP-CPF-HKG-0060] SEP 2019
